AU2003206014A1 - Neuropeptide receptor and uses thereof - Google Patents

Neuropeptide receptor and uses thereof

Info

Publication number
AU2003206014A1
AU2003206014A1 AU2003206014A AU2003206014A AU2003206014A1 AU 2003206014 A1 AU2003206014 A1 AU 2003206014A1 AU 2003206014 A AU2003206014 A AU 2003206014A AU 2003206014 A AU2003206014 A AU 2003206014A AU 2003206014 A1 AU2003206014 A1 AU 2003206014A1
Authority
AU
Australia
Prior art keywords
neuropeptide receptor
neuropeptide
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003206014A
Other versions
AU2003206014A8 (en
Inventor
Mark David Fidock
Nicola Melanie Robas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0204610A external-priority patent/GB0204610D0/en
Priority claimed from GB0223720A external-priority patent/GB0223720D0/en
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AU2003206014A8 publication Critical patent/AU2003206014A8/en
Publication of AU2003206014A1 publication Critical patent/AU2003206014A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
AU2003206014A 2002-02-27 2003-02-17 Neuropeptide receptor and uses thereof Abandoned AU2003206014A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0204610.0 2002-02-27
GB0204610A GB0204610D0 (en) 2002-02-27 2002-02-27 New use
GB0223720A GB0223720D0 (en) 2002-10-11 2002-10-11 New use
GB0223720.4 2002-10-11
PCT/IB2003/000601 WO2003073107A2 (en) 2002-02-27 2003-02-17 Neuropeptide receptor and uses thereof

Publications (2)

Publication Number Publication Date
AU2003206014A8 AU2003206014A8 (en) 2003-09-09
AU2003206014A1 true AU2003206014A1 (en) 2003-09-09

Family

ID=27736219

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003206014A Abandoned AU2003206014A1 (en) 2002-02-27 2003-02-17 Neuropeptide receptor and uses thereof

Country Status (4)

Country Link
EP (1) EP1340979A3 (en)
JP (1) JP2004033211A (en)
AU (1) AU2003206014A1 (en)
WO (1) WO2003073107A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006118328A1 (en) * 2005-04-28 2006-11-09 Takeda Pharmaceutical Company Limited Degranulation inhibitor
JP2009060787A (en) * 2005-11-15 2009-03-26 Gunma Univ Screening method and identification method for substance capable of inhibiting degranulation reaction in mast cell through rec168, and therapeutic agent for inflammatory disease concerned with mast cell containing rec168 antagonist
ES2659184T3 (en) * 2013-06-18 2018-03-14 Bayer Pharma Aktiengesellschaft MRG receiver modulators
EP3174987B1 (en) * 2014-08-01 2023-10-11 The Johns Hopkins University Mrgprx2/mrgprb2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions
CN110229228B (en) * 2019-05-31 2021-05-28 西安交通大学 Polypeptide with immunogenicity to anaphylactoid reaction specific receptor MRGPRX2 protein and application thereof
CN110229227B (en) * 2019-05-31 2021-05-28 西安交通大学 Polypeptide for preparing ELISA mouse monoclonal coating antibody and rabbit polyclonal detection antibody and application thereof
CN110204606B (en) * 2019-05-31 2021-04-20 西安交通大学 Polypeptide for preparing rabbit polyclonal antibody and application thereof
CN110240643B (en) * 2019-05-31 2021-05-28 西安交通大学 Polypeptide for preparing anaphylactoid reaction double-antibody sandwich kit paired antibody and application thereof
CN110204607B (en) * 2019-05-31 2021-04-20 西安交通大学 Dominant antigen epitope polypeptide of anti-Mrgprx 2 antibody and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1220914A1 (en) * 1999-09-16 2002-07-10 Solvay Pharmaceuticals B.V. Human g-protein coupled receptor
CA2413435A1 (en) * 2000-06-20 2001-12-27 Euroscreen S.A. A recombinant cell line expressing gpcrx11 as a functional receptor validated by angiopeptin and useful for screening of agonists and antagonists
AU2002317013B2 (en) * 2001-06-27 2007-11-01 Janssen Pharmaceutica N.V. EPF receptor assays, compounds and therapeutic compositions
AU2002330003A1 (en) * 2001-09-07 2003-03-24 Irm Llc Sensory neuron receptors

Also Published As

Publication number Publication date
WO2003073107A3 (en) 2004-03-04
WO2003073107A2 (en) 2003-09-04
AU2003206014A8 (en) 2003-09-09
EP1340979A2 (en) 2003-09-03
JP2004033211A (en) 2004-02-05
EP1340979A3 (en) 2004-02-04

Similar Documents

Publication Publication Date Title
WO2004040000A9 (en) G protein coupled receptors and uses thereof
AU2002314433A1 (en) Ephrin-tie receptor materials and methods
EP1539941A4 (en) Adzymes and uses thereof
AU2002347022A1 (en) Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
AU2003261974A1 (en) Amine compounds and use thereof
AUPS169202A0 (en) Neuropeptide assay
AU2003265202A1 (en) Novel lactams and uses thereof
AU2003254844A1 (en) Substituted amino compounds and use thereof
IL163868A0 (en) Hermiasterlin derivatives and uses thereof
SI1551805T1 (en) Substituted gamma-phenyl-delta-lactams and uses related thereto
AU2003271183A1 (en) Block copolymer and application thereof
AU2003296369A1 (en) Imminoamines and preparation thereof
AU2003225048A1 (en) Interfaces between semiconductor circuitry and transpinnor-based circuitry
AU2003281687A1 (en) Photopolymerizable composition and use thereof
AU2003225054A1 (en) Toll-like receptor 11 and toll-like receptor 12
AU2003299943A1 (en) Heterocycles and uses thereof
AU2003206014A1 (en) Neuropeptide receptor and uses thereof
AU2003281691A1 (en) Furoisoquinoline derivative and use thereof
AU2003231827A1 (en) Pseudo-tissues and uses thereof
AU2003302173A1 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
AU2003215379A1 (en) Substituted pyrimidinones and pyrimidinthiones
AU2003300396A1 (en) Chemokine antagonists and uses thereof
AU2003228397A1 (en) HAUSP-p53 INTERACTION AND USES THEREOF
AU2003300859A1 (en) Carrier-ligand fusions and uses thereof
AU2003216442A1 (en) Enkurin and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase